Log In
Print
BCIQ
Print
Print this Print this
 

DC-TC, TC-DC, Tumor Stem Cell Specific Dendritic Cell therapy, melapuldencel-T (NBS20) (formerly NBS-20)

  Manage Alerts
Collapse Summary General Information
Company NeoStem Inc.
DescriptionTumor cell-specific dendritic cell therapy
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPhase III
Standard IndicationMelanoma
Indication DetailsTreat metastatic melanoma; Treat recurrent stage III or IV metastatic melanoma
Regulatory Designation

U.S. - Fast Track (Treat metastatic melanoma);
U.S. - Orphan Drug (Treat metastatic melanoma);
U.S. - Special Protocol Assessment (Treat metastatic melanoma)

Partner

Cellular Biomedicine Group Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today